Minoxidil topique 2 % face à Cétirizine topique 1 %

In the minoxidil group, the average of Sinclair and shedding indices were 2.92 ± 0.81 and 4.27 ± 1.24 at the baseline, which was significantly decreased to 2.33 ± 0.90 and 3.20 ± 1.25 after 3 months (p-value of 0.076 and 0.026, respectively). In the cetirizine group, significant improvement was observed in the shedding scale. At the baseline, the average of Sinclair and shedding indices were 2.73 ± 0.75 and 4.18 ± 0.92, respectively, which decreased to 2.59 ± 0.90 and 3.71 ± 0.96 after 3 months (p-value of 0.185 and 0.032, respectively). According to ITT analysis, the two groups were not sig- nificantly different after 3 months of therapy, based on Sinclair and shedding scales (p value of 0.221 and 0.161, respectively).

Alavi SMK, Layegh P, Vahabi-Amlashi S et al.. Therapeutic effects of topical cetirizine in the treatment of female pattern hair loss: a randomized controlled noninferiority trial.. Expert Rev Clin Pharmacol 2023, DOI 10.1080/17512433.2023.2243813. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

In the minoxidil group, the average of Sinclair and shedding indices were 2.92 ± 0.81 and 4.27 ± 1.24 at the baseline, which was significantly decreased to 2.33 ± 0.90 and 3.20 ± 1.25 after 3 months (p-value of 0.076 and 0.026, respectively). In the cetirizine group, significant improvement was observed in the shedding scale. At the baseline, the average of Sinclair and shedding indices were 2.73 ± 0.75 and 4.18 ± 0.92, respectively, which decreased to 2.59 ± 0.90 and 3.71 ± 0.96 after 3 months (p-value of 0.185 and 0.032, respectively). According to ITT analysis, the two groups were not sig- nificantly different after 3 months of therapy, based on Sinclair and shedding scales (p value of 0.221 and 0.161, respectively).

Alavi SMK, Layegh P, Vahabi-Amlashi S et al.. Therapeutic effects of topical cetirizine in the treatment of female pattern hair loss: a randomized controlled noninferiority trial.. Expert Rev Clin Pharmacol 2023, DOI 10.1080/17512433.2023.2243813. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

In the minoxidil group, the average of Sinclair and shedding indices were 2.92 ± 0.81 and 4.27 ± 1.24 at the baseline, which was significantly decreased to 2.33 ± 0.90 and 3.20 ± 1.25 after 3 months (p-value of 0.076 and 0.026, respectively). In the cetirizine group, significant improvement was observed in the shedding scale. At the baseline, the average of Sinclair and shedding indices were 2.73 ± 0.75 and 4.18 ± 0.92, respectively, which decreased to 2.59 ± 0.90 and 3.71 ± 0.96 after 3 months (p-value of 0.185 and 0.032, respectively). According to ITT analysis, the two groups were not sig- nificantly different after 3 months of therapy, based on Sinclair and shedding scales (p value of 0.221 and 0.161, respectively).

Alavi SMK, Layegh P, Vahabi-Amlashi S et al.. Therapeutic effects of topical cetirizine in the treatment of female pattern hair loss: a randomized controlled noninferiority trial.. Expert Rev Clin Pharmacol 2023, DOI 10.1080/17512433.2023.2243813. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

In the minoxidil group, the average of Sinclair and shedding indices were 2.92 ± 0.81 and 4.27 ± 1.24 at the baseline, which was significantly decreased to 2.33 ± 0.90 and 3.20 ± 1.25 after 3 months (p-value of 0.076 and 0.026, respectively). In the cetirizine group, significant improvement was observed in the shedding scale. At the baseline, the average of Sinclair and shedding indices were 2.73 ± 0.75 and 4.18 ± 0.92, respectively, which decreased to 2.59 ± 0.90 and 3.71 ± 0.96 after 3 months (p-value of 0.185 and 0.032, respectively). According to ITT analysis, the two groups were not sig- nificantly different after 3 months of therapy, based on Sinclair and shedding scales (p value of 0.221 and 0.161, respectively).

Alavi SMK, Layegh P, Vahabi-Amlashi S et al.. Therapeutic effects of topical cetirizine in the treatment of female pattern hair loss: a randomized controlled noninferiority trial.. Expert Rev Clin Pharmacol 2023, DOI 10.1080/17512433.2023.2243813. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

During the 6-month treatment period, two patients in the minoxidil group (6.66%) were excluded due to hypertricho- sis. In the cetirizine group, three patients (10.00%) were excluded due to pruritus. One patient in cetirizine group and four patients in the minoxidil group noticed mild itch- ing but fulfilled the study protocol. Withdrawal of consent took place mainly due to the COVID-19 pandemic limita- tions. Although cetirizine’s side effects were higher than minoxidil’s, there was no statistically significant difference between the two groups (p = 0.444).

Alavi SMK, Layegh P, Vahabi-Amlashi S et al.. Therapeutic effects of topical cetirizine in the treatment of female pattern hair loss: a randomized controlled noninferiority trial.. Expert Rev Clin Pharmacol 2023, DOI 10.1080/17512433.2023.2243813. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

During the 6-month treatment period, two patients in the minoxidil group (6.66%) were excluded due to hypertricho- sis. In the cetirizine group, three patients (10.00%) were excluded due to pruritus. One patient in cetirizine group and four patients in the minoxidil group noticed mild itch- ing but fulfilled the study protocol. Withdrawal of consent took place mainly due to the COVID-19 pandemic limita- tions. Although cetirizine’s side effects were higher than minoxidil’s, there was no statistically significant difference between the two groups (p = 0.444).

Alavi SMK, Layegh P, Vahabi-Amlashi S et al.. Therapeutic effects of topical cetirizine in the treatment of female pattern hair loss: a randomized controlled noninferiority trial.. Expert Rev Clin Pharmacol 2023, DOI 10.1080/17512433.2023.2243813. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).